Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

EDINBURGH, Scotland & SAN DIEGO, March 19, 2025--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.